中国第二款，即科兴疫苗，土耳其第三期83.5%。10 weeks 内可生产出针对变异病毒的产品。2021.6.1 WHO批准

Reuters

WED FEB 17, 2021 / 12:49 PM EST

Sinovac vaccine works on UK, South African variants - Brazil institute​

Leonardo Benassatto

Photo


FILE PHOTO: A worker performs a quality check in the packaging facility of Chinese vaccine maker Sinovac Biotech, developing an experimental coronavirus disease (COVID-19) vaccine, during a government-organized media tour in Beijing, China, September 24, 2020.

REUTERS/THOMAS PETER/FILE PHOTO
SERRANA, Brazil (Reuters) -

The COVID-19 vaccine developed by China’s Sinovac Biotech is effective against the UK and South African variants, the vaccine's Brazilian partner said on Wednesday, citing test results in Chinese trials.

"We have tested this vaccine in China against the English and the South African variants, with good results," said Dimas Covas, head of the Butantan biomedical center in Sao Paulo which lead domestic trials of the Chinese vaccine and is supplying doses to Brazil's Health Ministry.

Covas did not give any more details on exactly how effective the vaccine proved against these strains.

Butantan is also testing the vaccine, known as CoronaVac, against the Brazilian variant of the virus which appeared in the city of Manaus, he said.

"Soon we will have the results and we are very positive it will do the job," Covas said.

Covas was speaking at a news conference in the small city of Serrana, in the interior of Sao Paulo state, where Butantan began on Wednesday a mass vaccination campaign aimed at inoculating the entire adult population against COVID-19 to test whether it lowers the infection rate.

Covas said he expects CoronaVac to have an advantage over other vaccines due to the technology it uses - an inactivated version of a coronavirus strain.

The efficacy of the Chinese vaccine against the Brazilian strain in particular will be vital to Brazil. The government has secured 100 million doses and made the vaccine a centerpiece of its inoculation campaign.

Covas' comments come as several cities in Brazil, including state capitals of Rio, Salvador and Cuiaba have suspended new vaccinations as they ran out of doses.
 

新加坡收到中国科兴首批冠病疫苗​


2021年2月24日 10:20 PM文/陈劲禾
新加坡昨天收到中国科兴控股生物技术公司生产的第一批冠病疫苗。（彭博社）


新加坡昨天收到中国科兴控股生物技术公司生产的第一批冠病疫苗。（彭博社）


（早报讯）新加坡昨天收到中国科兴控股生物技术公司生产的第一批冠病疫苗，不过这款疫苗还未获准在本地使用。

根据卫生部今晚（2月24日）发布的文告，科兴（Sinovac）已提交数据，卫生科学局按照“大流行病特别采用程序”针对制造过程、安全性和疫苗效能展开了科学评估。
 
老向，有前大家一起赚。我给你打工？
 

杜特尔特要当面感谢习近平　透露中国给菲捐疫苗时的特殊举动​


2021-03-01

中国2月28日向菲律宾捐赠了新冠肺炎（COVID-19）疫苗，菲律宾总统杜特尔特（Rodrigo Duterte）赴机场迎接，并指出中国在给菲律宾捐疫苗时的特殊举动。

中国军机2月28日将60万剂科兴新冠疫苗运送到菲律宾首都马尼拉。（Twitter@ChineseEmbassyManila）

这些新冠疫苗是由北京科兴生物公司研发生产的。（Twitter@ChineseEmbassyManila）

工作人员将新冠疫苗从飞机运送出来。（Twitter@ChineseEmbassyManila）

菲律宾总统杜特尔特（左3）高级官员陪同下，赴机场迎接中国新冠疫苗。中国驻菲律宾大使黄溪连（左2）也赴现场迎接疫苗。（Twitter@ChineseEmbassyManila）

杜特尔特赴机场迎接中国新冠疫苗，足见其对这批疫苗的重视。（Twitter@ChineseEmbassyManila）

+3

2月28日，中国空军出动运-20运输机，将60万剂、首批科兴新冠疫苗运送到菲律宾首都马尼拉维拉莫尔军用机场，这是菲律宾自疫情爆发以来接收的首批新冠疫苗。

菲律宾总统杜特尔特当天赴机场迎接，并发表了讲话。杜特尔特说，中国的疫苗让菲律宾朝着击败新冠病毒（SARS-CoV-2）又迈出了一步。

他还感谢了中国人民和中国政府，并表示希望在2021年年底，疫情稳定下来后，访问中国，当面感谢中国国家主席习近平。

杜特尔特还透露，中国在给菲律宾援助疫苗时，是亲自派专机运送的。他说：“中国已经向多个国家捐赠了一些疫苗，但只有向菲律宾捐赠的疫苗，是由中国政府专机亲自运送的。”

首批中国新冠疫苗抵达　杜特尔特激动致辞：要当面感谢习近平[图]

根据中国外交部透露的数据，中国目前已经向50多个国家捐赠了新冠疫苗，同时也正向20多个愿意购买中国疫苗的国家出口疫苗。

接收到中国新冠疫苗后，菲律宾迅速开展了接种计划。菲律宾新闻网站Rappler3月1日报道，3月1日上午，菲律宾国立大学-菲律宾总医院院长黎牙实备（Gerardo Legaspi）接种新冠疫苗，他是该国首位接种者。菲律宾政府希望在2021年年底前，努力使5,000万民众接种新冠疫苗。
 
中国科兴疫苗有效率83.5％ 100%避免住院


中国科兴生物（Sinovac）研发的疫苗（简称“科兴疫苗”）在全球多国测试，土耳其国营媒体3月3日引述哈切特佩大学（Hacettepe University）报道，科兴疫苗在当地的最终第3期试验有效率为83.5%。


没有出现重大副作用


土耳其科学谘询委员会成员于纳尔（Serhat Unal）表示，由于在测试中没有出现重大副作用，加上目前土耳其已广泛接种科兴疫苗，没有副作用报告，所以“我们能容易地说这是安全的。”

哈切特佩大学表示，根据第3期试验的最终数据，疫苗有效率为83.5%，另外疫苗在全部100%个案都能避免接种者住院及出现重症。

土耳其研究人员之前在2020年12月24日称，根据第3期临床试验中期数据显示，科兴疫苗有效率为91.25%，如今则为第3期试验的最终数字。

路透社报道，有10,216人参与有关测试，当中男性佔58%，全数为18至59岁。

第3期测试的参与者中，最终有41人感染新冠病毒，当中32人属于安慰剂组，全部个案都能避免住院及出现重症。在测试内，6名住院者都来自安慰剂组。

科兴自2020年7月21日起陆续选择在南美洲的巴西、智利，东南亚的印尼和中东的土耳其这四个处于不同地域的国家开展疫苗的第3期临床研究。

科兴之前在2021年2月初表示，在巴西的第3期临床研究显示，疫苗的预防保护力为50.65%，就医保护力为83.70%，对住院、重症及死亡病例的保护效力为100%。该测试是针对巴西18岁及以上医务人员的研究，共有12,396名受测试者，获得253宗监测期有效病例。

目前土耳其已展开疫苗接种计划，总统埃尔多安（Recep Tayyip Erdoğan）1月14日透过电视广播接种科兴疫苗，他所属正义与发展党的发言人指，此举是希望释除公众对疫苗的疑虑。
 
2 hr 13 min ago

Mexico will begin using China’s Sinovac coronavirus vaccine​

From CNN’s Natalie Gallon

A vial of the Sinovac vaccine against COVID-19 is pictured at the Habitat nursing home in Medellin, Colombia, on February 26.
A vial of the Sinovac vaccine against COVID-19 is pictured at the Habitat nursing home in Medellin, Colombia, on February 26. Joaquin Sarmiento/AFP/Getty Images

Mexico will begin to administer China’s Sinovac Covid-19 vaccine starting this weekend, the country’s Secretary of Foreign Affairs, Marcelo Ebrard, said.

“Good news: we received the Certificate of Analysis for the Sinovac vaccine. It can be applied from this weekend throughout the country,” Ebrard said on his official Twitter account Friday.
点击展开...

Sinovac will be the fourth vaccine to be administered in Mexico as the country is already using Pfizer-BioNTech, AstraZenica and Sputnik V.

The country's latest figures: Mexico continues to have the third largest death toll in the world with at least 188,866 Covid-19 deaths and 2,112,508 confirmed cases according to Johns Hopkins University, though the country has started to see a decline in both.

They have administered a total of at least 2,676,035 doses throughout the country according to Mexico’s Ministry of Health.
 
Reuters

FRI MAR 5, 2021 / 2:33 AM EST

Sinovac vaccine may not trigger sufficient antibody response to Brazil variant: study​



Photo

FILE PHOTO: A nurse receives a dose of the Sinovac's coronavirus disease (COVID-19) vaccine, after Brazil health regulator Anvisa approved its emergency use at Hospital das Clinicas in Sao Paulo, Brazil January 17, 2021.
REUTERS/AMANDA PEROBELLI/FILE PHOTO

(Reuters) - Sinovac Biotech's COVID-19 vaccine may not trigger sufficient antibody responses against a new variant identified in Brazil, a small-sample lab study showed.

The emergence of variants of the new coronavirus has raised concern that vaccines and treatments that were developed based on previous strains may not work as robustly.

Plasma samples taken from eight people vaccinated with Sinovac's CoronaVac failed to efficiently neutralize the P.1 lineage variant, or 20J/501Y.V3, researchers said in a paper published on Monday ahead of peer-review。

"These results suggest that P.1 virus might escape from neutralizing antibodies induced by... CoronaVac," researchers at the University of São Paulo in Brazil, Washington University School of Medicine in the United States, and a few other institutions said in the paper.


CoronaVac is being used in mass vaccination drives in countries including China, Brazil, Indonesia and Turkey.


Although the study suggests re-infection may occur in vaccinated individuals, the protection given by CoronaVac against severe COVID-19 may indicate other mechanisms in the human immune system, aside from antibodies, may also contribute to reducing disease severity, researchers said.

A Sinovac spokesman was not immediately available for comment. Chief executive Yin Weidong said in a programme aired by state-backed broadcaster CGTN on Thursday the company is "fully capable" of using current research and manufacturing capacity to develop a new vaccine against variants if necessary.

He also said the process would take much less time than it took to develop CoronaVac.
 

独家：研究表明中国科兴疫苗对巴西P1新冠病毒变体有效--消息​

路透新闻部

路透圣保罗3月8日 - 熟悉巴西一项研究的消息人士周一告诉路透，巴西此项研究的初步数据表明，中国科兴生物研发的COVID-19疫苗对首次在巴西发现的病毒P1变体有效。

这位消息人士说，这项研究对已接种疫苗者的血液进行了新冠病毒巴西变体的检测。但该消息人士未提供数据细节。科兴生物疫苗Coronavac是目前巴西接种使用的主要新冠疫苗。(完)

编译 刘秀红；审校 陈宗琦

cn.reuters.com

Reuters | Breaking International News & Views

Find latest news from every corner of the globe at Reuters.com, your online source for breaking international news coverage.
cn.reuters.com cn.reuters.com
 
您必须登录或注册才可回复。
后退
顶部